Re­gen­eron to seek EUA for low­er dose of Covid-19 mAb cock­tail as new tri­al shows ma­jor drop in risk of hos­pi­tal­iza­tion or death

The suc­cess of mon­o­clon­al an­ti­body (mAb) cock­tails in keep­ing peo­ple with Covid-19 out of the hos­pi­tal con­tin­ued Tues­day, with Re­gen­eron an­nounc­ing that even a low­er-than-au­tho­rized dose of its com­bi­na­tion of mAbs re­duced hos­pi­tal­iza­tion or death by 70% in non-hos­pi­tal­ized Covid-19 pa­tients.

“We will rapid­ly dis­cuss the new da­ta with reg­u­la­to­ry au­thor­i­ties and re­quest that the 1,200 mg dose be added to the U.S. Emer­gency Use Au­tho­riza­tion, in or­der for the an­tic­i­pat­ed RE­GEN-COV sup­ply to be avail­able to treat even more pa­tients,” George Yan­copou­los, pres­i­dent and CSO of Re­gen­eron, said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.